A Randomized, Controlled, Multicenter Study to Evaluate Efficacy and Safety of Fibrin Sealant VH S/D for Hemostasis in Subjects Undergoing Total Hip Replacement

Baxter Healthcare Corporation7 sites in 3 countriesAugust 2001

ConditionsHip Replacement Surgery

DrugsFibrin Sealant Vapor-Heated Solvent/Detergent-treated

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Hip Replacement Surgery
Sponsor: Baxter Healthcare Corporation
Locations: 7
Status: Completed
Last Updated: 19 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of the study is to monitor the safety of FS VH S/D and evaluate whether FS VH S/D is superior to standard treatment in reducing blood loss in subjects undergoing total hip replacement with cement-free hip prostheses.

Registry

clinicaltrials.gov

Start Date

August 2001

End Date

March 2003

Last Updated

19 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Baxter Healthcare Corporation

Eligibility Criteria

Inclusion Criteria

•Each subject to be included into the study must fulfill the following inclusion criteria:
•Subjects receiving a cement free hip prosthesis due to coxarthrosis because of primary or dysplastic arthrosis grade 1 - 3 according to Crowe or rheumatoid arthritis as well as subjects receiving a cement free hip prosthesis due to femur head necrosis (Crowe classification).
•ASA and NSAIDs have been discontinued one week prior to surgery
•Written informed consent
•Male and female at least 19 years of age

Exclusion Criteria

•Subjects fulfilling the following exclusion criteria will not be recruited into the study:
•Impaired coagulation
•Previous hip surgery
•Acetabular roof plastic
•Known hypersensitivity to aprotinin or other components of the product
•Immunodeficiency
•Increased red cell production
•Pregnant or lactating women (positive urine or serum pregnancy test; this test is required of any female subject who is not post menopausal or surgically sterilized).
•Subjects concurrently participating in another clinical trial or having received another investigational drug within the last 30 days.
•Also patients with abnormal coagulation values due to anticoagulants like coumadins or heparin must be excluded.